Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT02844816

Recurrent Bladder Urothelial Carcinoma Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 +1 more

COMPLETED PHASE2

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

NCT06059547

Bladder Cancer Adult Solid Tumor

ACTIVE_NOT_RECRUITING PHASE2

Intravesical Gem/Doce in Patients With NMIBC

NCT05644041

Urinary Bladder Cancer

RECRUITING PHASE2

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

NCT02720367

Urinary Bladder Cancer

COMPLETED PHASE1

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

NCT02792192

Bladder Cancer

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. This study will also search for genes involved in the response to treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Temsirolimus

Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.

Group Type EXPERIMENTAL

Temsirolimus

Intervention Type DRUG

Temsirolimus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temsirolimus

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Torisel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women of at least 18 years of age
* Histologically proven Bladder cancer
* Locally advanced or metastatic disease (stage IV)
* Functional status (ECOG / OMS) ≤ 2
* Relapse after first-line chemotherapy
* Measurable lesions (RECIST criteria)
* Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.
* Biological levels :
* Neutrophil count \>1,5.109/L.
* Platelets \>100.109/L
* Total serum bilirubin \< 1.5 × ULN
* Clearance of créatinine 40 ml/mm
* If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 × ULN
* With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<5 × ULN
* Signed informed consent
* Both women and men must agree to use a medically acceptable method of contraception throughout the study. Women of childbearing potential must have a negative serum pregnancy test of or less than 7 days before the first perfusion of study.
* France only : Patients affiliated to a social security program

Exclusion Criteria

* Presence of metastatic brain or meningeal tumors on selection scanner, weither symptomatic or asymptomatic
* Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion
* Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or polysorbate 80 or to their excipients
* Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma curatively treated) or incidental (≤ pT2) prostate cancer found on a radical cystoprostatectomy material
* The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on the 30th day ( or at least 7 halves-lives, according to the shortest duration) before the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be purposely excluded.
* Auto-immune pathology, psychiatric or neurological disorder
* Any unstable medical condition
* Unstable cardiac disease
* Severe renal failure
* Unstable diabetes
* Pregnancy
* Patient enrolled in another therapeutic clinical trial
* Patient unable to follow and comply with the study procedures because of any geographical, social or medical condition
* Patient partially or totally deprived of his civil rights

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No